Seagen Inc. Insider Trading for August 2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Seagen Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Seagen Inc. for August 2020.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Aug 25 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | M | 26.10 | 3,831 | 99,989 | 0 | |
Aug 25 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | M | 15.46 | 6,468 | 99,995 | 0 | |
Aug 25 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Buy | M | 15.46 | 6,468 | 99,995 | 729,560 | 723.1 K to 729.6 K (+0.89 %) |
Aug 25 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Buy | M | 26.10 | 3,831 | 99,989 | 723,092 | 719.3 K to 723.1 K (+0.53 %) |
Aug 20 2020 | SGEN | SEATTLE GENETICS I ... | LIU JEAN I | GC/EVP, Leg Affairs | Sell | S | 158.17 | 6,846 | 1,082,823 | 63,946 | 70.8 K to 63.9 K (-9.67 %) |
Aug 20 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 158.17 | 9,262 | 1,464,959 | 142,554 | 151.8 K to 142.6 K (-6.10 %) |
Aug 20 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 158.17 | 27,060 | 4,280,053 | 719,261 | 746.3 K to 719.3 K (-3.63 %) |
Aug 20 2020 | SGEN | SEATTLE GENETICS I ... | ROMP CHARLES R | EVP, Commercial | Sell | S | 158.17 | 4,027 | 636,941 | 59,075 | 63.1 K to 59.1 K (-6.38 %) |
Aug 20 2020 | SGEN | SEATTLE GENETICS I ... | HIMES VAUGHN B | Chief Technical Off ... | Sell | S | 158.17 | 8,054 | 1,273,892 | 190,414 | 198.5 K to 190.4 K (-4.06 %) |
Aug 18 2020 | SGEN | SEATTLE GENETICS I ... | LOVE TED W | Director | Option Exercise | A | 161.82 | 4,460 | 721,717 | 4,460 | |
Aug 18 2020 | SGEN | SEATTLE GENETICS I ... | LOVE TED W | Director | Grant | A | 0.00 | 1,799 | 0 | 1,799 | 0 to 1.8 K |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | DANSEY ROGER D | Chief Medical Offic ... | Option Exercise | A | 161.82 | 32,073 | 5,190,053 | 32,073 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | DANSEY ROGER D | Chief Medical Offic ... | Option Exercise | A | 161.82 | 636 | 102,918 | 636 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | DANSEY ROGER D | Chief Medical Offic ... | Sell | S | 157.79 | 450 | 71,006 | 122,493 | 122.9 K to 122.5 K (-0.37 %) |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | DANSEY ROGER D | Chief Medical Offic ... | Grant | A | 0.00 | 13,192 | 0 | 122,943 | 109.8 K to 122.9 K (+12.02 %) |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | A | 161.82 | 68,747 | 11,124,640 | 68,747 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | A | 161.82 | 636 | 102,918 | 636 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Grant | A | 0.00 | 27,982 | 0 | 746,321 | 718.3 K to 746.3 K (+3.90 %) |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | DANSEY ROGER D | Chief Medical Offic ... | Option Exercise | A | 161.82 | 32,073 | 5,190,053 | 32,073 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | DANSEY ROGER D | Chief Medical Offic ... | Option Exercise | A | 161.82 | 636 | 102,918 | 636 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | DANSEY ROGER D | Chief Medical Offic ... | Sell | S | 157.79 | 450 | 71,006 | 122,493 | 122.9 K to 122.5 K (-0.37 %) |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | DANSEY ROGER D | Chief Medical Offic ... | Grant | A | 0.00 | 13,192 | 0 | 122,943 | 109.8 K to 122.9 K (+12.02 %) |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | ROMP CHARLES R | EVP, Commercial | Option Exercise | A | 161.82 | 18,711 | 3,027,814 | 18,711 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | ROMP CHARLES R | EVP, Commercial | Option Exercise | A | 161.82 | 617 | 99,843 | 617 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | ROMP CHARLES R | EVP, Commercial | Grant | A | 0.00 | 7,795 | 0 | 63,102 | 55.3 K to 63.1 K (+14.09 %) |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 161.82 | 20,774 | 3,361,649 | 20,774 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 161.82 | 636 | 102,918 | 636 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Grant | A | 0.00 | 8,635 | 0 | 151,816 | 143.2 K to 151.8 K (+6.03 %) |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | A | 161.82 | 68,747 | 11,124,640 | 68,747 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | A | 161.82 | 636 | 102,918 | 636 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Grant | A | 0.00 | 27,982 | 0 | 746,321 | 718.3 K to 746.3 K (+3.90 %) |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | HIMES VAUGHN B | Chief Technical Off ... | Option Exercise | A | 161.82 | 15,719 | 2,543,649 | 15,719 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | HIMES VAUGHN B | Chief Technical Off ... | Option Exercise | A | 161.82 | 636 | 102,918 | 636 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | HIMES VAUGHN B | Chief Technical Off ... | Grant | A | 0.00 | 6,596 | 0 | 198,468 | 191.9 K to 198.5 K (+3.44 %) |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | LIU JEAN I | GC/EVP, Legal Affai ... | Option Exercise | A | 161.82 | 17,205 | 2,784,113 | 17,205 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | LIU JEAN I | GC/EVP, Legal Affai ... | Option Exercise | A | 161.82 | 636 | 102,918 | 636 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | LIU JEAN I | GC/EVP, Legal Affai ... | Grant | A | 0.00 | 7,195 | 0 | 70,792 | 63.6 K to 70.8 K (+11.31 %) |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | ROMP CHARLES R | EVP, Commercial | Option Exercise | A | 161.82 | 18,711 | 3,027,814 | 18,711 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | ROMP CHARLES R | EVP, Commercial | Option Exercise | A | 161.82 | 617 | 99,843 | 617 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | ROMP CHARLES R | EVP, Commercial | Grant | A | 0.00 | 7,795 | 0 | 63,102 | 55.3 K to 63.1 K (+14.09 %) |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 161.82 | 20,774 | 3,361,649 | 20,774 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 161.82 | 636 | 102,918 | 636 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Grant | A | 0.00 | 8,635 | 0 | 151,816 | 143.2 K to 151.8 K (+6.03 %) |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | HIMES VAUGHN B | Chief Technical Off ... | Option Exercise | A | 161.82 | 15,719 | 2,543,649 | 15,719 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | HIMES VAUGHN B | Chief Technical Off ... | Option Exercise | A | 161.82 | 636 | 102,918 | 636 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | HIMES VAUGHN B | Chief Technical Off ... | Grant | A | 0.00 | 6,596 | 0 | 198,468 | 191.9 K to 198.5 K (+3.44 %) |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | LIU JEAN I | GC/EVP, Legal Affai ... | Option Exercise | A | 161.82 | 17,205 | 2,784,113 | 17,205 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | LIU JEAN I | GC/EVP, Legal Affai ... | Option Exercise | A | 161.82 | 636 | 102,918 | 636 | |
Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | LIU JEAN I | GC/EVP, Legal Affai ... | Grant | A | 0.00 | 7,195 | 0 | 70,792 | 63.6 K to 70.8 K (+11.31 %) |
Aug 13 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | M | 12.00 | 4,619 | 55,428 | 0 | |
Aug 13 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | M | 12.00 | 2,354 | 28,248 | 4,619 | |
Aug 13 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | M | 12.00 | 11,616 | 139,392 | 6,973 | |
Aug 13 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | M | 12.00 | 9,486 | 113,832 | 18,589 | |
Aug 13 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | M | 12.00 | 400 | 4,800 | 28,075 | |
Aug 13 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 154.76 | 4,619 | 714,836 | 718,339 | 723 K to 718.3 K (-0.64 %) |
Aug 13 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Buy | M | 12.00 | 4,619 | 55,428 | 722,958 | 718.3 K to 723 K (+0.64 %) |
Aug 13 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 155.96 | 2,354 | 367,130 | 718,339 | 720.7 K to 718.3 K (-0.33 %) |
Aug 13 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Buy | M | 12.00 | 2,354 | 28,248 | 720,693 | 718.3 K to 720.7 K (+0.33 %) |
Aug 13 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 156.89 | 11,616 | 1,822,434 | 718,339 | 730 K to 718.3 K (-1.59 %) |
Aug 13 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Buy | M | 12.00 | 11,616 | 139,392 | 729,955 | 718.3 K to 730 K (+1.62 %) |
Aug 13 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 157.63 | 9,486 | 1,495,278 | 718,339 | 727.8 K to 718.3 K (-1.30 %) |
Aug 13 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Buy | M | 12.00 | 9,486 | 113,832 | 727,825 | 718.3 K to 727.8 K (+1.32 %) |
Aug 13 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 158.96 | 400 | 63,584 | 718,339 | 718.7 K to 718.3 K (-0.06 %) |
Aug 13 2020 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Buy | M | 12.00 | 400 | 4,800 | 718,739 | 718.3 K to 718.7 K (+0.06 %) |
Aug 05 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 166.74 | 1,905 | 317,640 | 143,181 | 145.1 K to 143.2 K (-1.31 %) |
Aug 05 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 166.10 | 10,375 | 1,723,288 | 145,086 | 155.5 K to 145.1 K (-6.67 %) |
Aug 05 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 164.96 | 7,720 | 1,273,491 | 155,461 | 163.2 K to 155.5 K (-4.73 %) |